^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Diffuse Large B Cell Lymphoma
    Drug:Xpovio (selinexor) (XPO1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    Karyopharm Press Release
    Title:

    Karyopharm Announces XPOVIO® (selinexor) Receives Regulatory Approval in Israel for the Treatment of Patients with Multiple Myeloma and Diffuse Large B-Cell Lymphoma

    Published date:
    02/04/2021
    Excerpt:
    Karyopharm Therapeutics Inc...has received a principal approval letter from the Israeli Ministry of Health, Israel's regulatory agency responsible for the approval of new medicines, granting the approval of XPOVIO® (selinexor) for the treatment of patients with either multiple myeloma or diffuse large B-cell lymphoma (DLBCL). The approved indications for XPOVIO...for the treatment of adult patients with relapsed or refractory DLBCL, not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy.
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    FDA
    Excerpt:
    XPOVIO is a nuclear export inhibitor indicated:...For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy...
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    PRNewswire
    Title:

    XPOVIO® (selinexor) Approved for New Indication in DLBCL in China, Bringing a New Treatment Option to Patients in the Country

    Published date:
    07/05/2024
    Excerpt:
    Antengene Corporation...today announced that the China National Medical Products Administration (NMPA) has approved a new indication of XPOVIO® (selinexor) as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Diffuse Large B-cell Lymphoma: Third-line and Subsequent Therapy…Selinexor (only after at least two lines of systemic therapy) Histologic Transformation of Indolent Lymphomas to DLBCL….Other recommended regimens...Selinexor (transformed FL; only after at least two lines of systemic therapy; including patients with disease progression after transplant or CAR T-cell therapy)
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Karyopharm Press Release
    Title:

    Karyopharm’s Selinexor Receives Fast Track Designation from FDA for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma

    Published date:
    11/07/2018
    Excerpt:
    Karyopharm Therapeutics Inc...announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to selinexor, the Company’s first-in-class, oral SINE compound for the treatment of patients with diffuse large B-cell lymphoma (DLBCL)...Selinexor is currently being studied in the ongoing Phase 2b SADAL study in patients with relapsed or refractory DLBCL who are not eligible for stem cell transplantation...